Executive of Rare Disease Drug Developer Automatically Sells Portion of Shares Worth 8 Billion Won

BridgeBio Pharma, Inc. (NASDAQ: BBIO), a rare disease therapy developer listed on the Nasdaq, disclosed that CEO Neil Kumar sold approximately 80,000 shares on April 9 and 10 through two trust accounts set up for inheritance and gift planning, under a Rule 10b5-1 trading plan. According to the filing, the total proceeds amounted to about $5.97 million (roughly KRW 8 billion), and even after these transactions, he still holds several million shares across the trusts and in his own name.

Meanwhile, since the U.S. launch of its cardiac amyloidosis treatment Attruby, prescriptions have climbed rapidly, and the company sustained top-line growth in its early commercialization phase, posting 2025 revenues of about $500 million (approximately KRW 650 billion). In addition, an interim analysis of the Phase 3 FORTIFY trial of BBP-418—an oral therapy for the rare muscular disease LGMD2I R9—confirmed consistent efficacy and safety. BridgeBio plans to submit a New Drug Application to the U.S. Food and Drug Administration in the first half of 2026, targeting a U.S. launch in late 2026 to early 2027.

Founded in 2015 and based in Palo Alto, California, BridgeBio Pharma focuses on developing gene- and precision-medicine–based therapies for patients with genetic and rare diseases. The company’s late-stage clinical pipeline includes treatments for cardiac amyloidosis (Attruby), muscular dystrophy and achondroplasia, among other genetic rare disorders.